menu
    • menu
    [{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"AZD5904","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Conduit Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition Corp."},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Murphy Canyon Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"AZD5904","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Conduit Pharma \/ Murphy Canyon Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Murphy Canyon Acquisition"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"AZD1656","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Conduit Pharma \/ Conduit Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Conduit Pharma"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AZD1656","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Conduit Pharma \/ Conduit Pharma","highestDevelopmentStatusID":"14","companyTruncated":"Conduit Pharma \/ Conduit Pharma"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"AZD1656","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Conduit Pharma \/ AstraZeneca","highestDevelopmentStatusID":"14","companyTruncated":"Conduit Pharma \/ AstraZeneca"}]

    Find Clinical Drug Pipeline Developments & Deals by Conduit Pharma

    Menu

    Conduit Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD1656

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Conduit Pharma Selects Initial Indications for Autoimmune Disorder Candidate

                            Details : AZD1656, a HK-4 glucokinase activator, is now being repurposed by Conduit for for the treatment of systemic lupus erythematosus (including lupus nephritis) and ANCA-associated vasculitis.

                            Brand Name : AZD1656

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2024

                            Lead Product(s) : AZD1656

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD1656

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Conduit Pharmaceuticals Signs Exclusive License with AstraZeneca for Novel Treatments

                            Details : Through the License Agreement, Conduit will analyze existing clinical data and initiate Phase II trial studies of AZD1656 for treating Lupus Nephritis and Renal Transplant.

                            Brand Name : AZD1656

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 08, 2024

                            Lead Product(s) : AZD1656

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Recipient : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD1656

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : ClinConnect

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ClinConnect Partners with Conduit Pharmaceuticals on Cocrystal Development Program for AZD1656

                            Details : ClinConnect in partnership with Conduit, will seek to identify, characterize, and validate suitable cocrystal partners for AZD1656 to solve for current challenges associated with solubility, stability, and bioavailability.

                            Brand Name : AZD1656

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 11, 2023

                            Lead Product(s) : AZD1656

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : ClinConnect

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD5904

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Murphy Canyon Acquisition

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

                            Details : The combined company will accelerate development of Conduit’s autoimmune disease and idiopathic male infertility pipeline, including AZD5904, a potent orally bioavailable MPO inhibitor.

                            Brand Name : AZD5904

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 22, 2023

                            Lead Product(s) : AZD5904

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Murphy Canyon Acquisition

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Conduit Pharma

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD5904

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Murphy Canyon Acquisition Corp.

                            Deal Size : $27.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Conduit Pharmaceuticals to Become a Publicly Traded Company via Merger with Murphy Canyon Acquisition Corp.

                            Details : AZD5904 is a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

                            Brand Name : AZD5904

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 09, 2022

                            Lead Product(s) : AZD5904

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Murphy Canyon Acquisition Corp.

                            Deal Size : $27.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth